The US Food and Drug Administration (FDA) was busy in 2023 with significant, and even bullish, developments occurring across several areas, from drug and biologic development and manufacturing to labeling, advertising, and promotion guidance.

The overall theme of 2023 at FDA was finding innovative ways to address existing regulatory obligations, especially in light of new and novel technologies, taking into account lessons learned from COVID-19–era roadblocks and innovations.